CONCORDBIO

- Concall Schedule - Concall Date: 26th August 2026 - Concall Time: 01:00 PM to 03:00 PM (IST)

- Q1 FY27 revenue grew by 26.2% YoY to INR257 crores. - EBITDA increased by 34% YoY to INR82 crores, with margins at 32% (▲190 bps YoY). - PAT grew by 31% YoY to INR58 crores, with margins at 22.4% (▲80 bps YoY). - Management aims for INR3,000 crores total revenue in 5-6 years, leveraging existing API and formulation capacities (INR2,200 Cr from API, INR600-700 Cr from formulation). - Injectable facility is commercialized, currently at 5% utilization, with sales to emerging markets expected to start next year; H2 FY27 to focus on domestic contract manufacturing. - EBITDA margins are projected to improve, targeting 40% by FY28 with full ramp-up of new businesses (injectable, Stellon).

- Earnings Call for Q1 FY27 (Quarter ended June 30, 2026) was conducted on August 03, 2026. - The audio recording of the conference call is now available on the company's website.

- Consolidated Revenue ₹257 Cr vs ₹204 Cr (▲26.2% YoY) - EBITDA ₹82 Cr vs ₹61 Cr (▲34.2% YoY) - PAT ₹58 Cr vs ₹44 Cr (▲31.0% YoY) - EBITDA Margin 32.0% vs 30.1% (▲190bps)

- Concord Biotech Limited held its 41st Annual General Meeting (AGM) on July 31, 2026. - All six resolutions, including the adoption of financial statements, declaration of dividend, director appointments, and approval of enhanced limits for inter-corporate loans/guarantees, were passed with requisite majority.

- The 41st Annual General Meeting (AGM) of Concord Biotech Limited was held on July 31, 2026, via Video Conferencing. - The Chairman presented on FY26 operations, financial performance, and future prospects. - Statutory and Secretarial Audit Reports had no qualifications or adverse remarks. - Voting results will be declared within two working days.

- Consolidated Revenue ₹257.49 Cr vs ₹203.99 Cr (▲26.22% YoY) - EBITDA ₹83.65 Cr vs ₹62.89 Cr (▲33.01% YoY) - PAT ₹57.70 Cr vs ₹44.06 Cr (▲30.95% YoY) - EBITDA Margin 32.49% vs 30.83% (▲166bps)

- Concall Schedule - Concall Date: Monday, August 03, 2026 - Concall Time: 3:30 P.M. IST

- 41st Annual General Meeting (AGM) scheduled for Friday, July 31, 2026, at 12:00 Noon. - Record Date for final dividend for FY ended March 31, 2026, is Friday, July 24, 2026. - Book Closure from Saturday, July 25, 2026, to Friday, July 31, 2026. - Dividend payment, if approved, will be by August 30, 2026.

- 41st Annual General Meeting (AGM) on July 31, 2026, via VC/OAVM. The record date for e-voting and dividend is July 24, 2026. - Board recommended a dividend of ₹7.55 per equity share (755%) for FY 2025-26. - Proposed appointment of Mrs. Ekta Gupta as an Independent Director for 5 years. - Proposal to enhance inter-corporate loan/guarantee limits to ₹500 Crores.

- The trading window for equity shares will be closed from July 01, 2026. - It will reopen 48 hours after the Unaudited Financial Results for the quarter ended June 30, 2026, are declared.

- Successful completion of inspection by Pharmacy and Poisons Board (Kenya) and National Drug Authority (Uganda) at Unit-II formulation facility. - The inspection was conducted from June 18, 2026, to June 24, 2026. - This reinforces the company's commitment to quality and strengthens its global manufacturing and regulatory footprint.

- Concord Biotech Limited to acquire 27.38% equity share capital in M/s FSGE Renewable Power Private Limited for ₹6.3 Crores. - FSGE is setting up a Hybrid Wind Solar Power Project (6.3 MW AC Wind & 6.3 MWp DC Solar) in Gujarat for Concord Biotech's Limbasi Facility. - The investment aligns with the company's sustainability commitment, aims to reduce its carbon footprint, and offers long-term financial benefits through energy cost reduction.

- Investor Meetings Scheduled - Date: 24th & 25th June 2026 - Time: 10:00 am onwards - Organized by: Kotak Institutional Equities - Nature: 1x1 / Group Meeting in Mumbai

- Schedule of Analyst / Institutional Investor meetings - Meeting Date: 17th June 2026 - Meeting Time: 10:30 am onwards - Mode: Virtual

- Concord Biotech Limited announced the successful completion of an ANVISA inspection by the Brazilian Health Regulatory Agency at its Limbasi API Manufacturing Facility, conducted from June 8-12, 2026. This strengthens regulatory compliance and supports international expansion into key pharmaceutical markets.

- Concord Biotech received USFDA approval for its Abbreviated New Drug Application (ANDA) for Tofacitinib Tablets, 5 mg and 10 mg. - Tofacitinib Tablets are indicated for the treatment of various adult and juvenile autoimmune conditions. - The U.S. market for Tofacitinib Tablets is estimated at approximately US$ 500 million. - This approval is expected to enhance the company's product offerings and support long-term growth.